97 related articles for article (PubMed ID: 33480647)
1. Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma.
Goldin AN; Singh A; Joshi S; Jamieson C; Durden DL
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e304-e311. PubMed ID: 33480647
[TBL] [Abstract][Full Text] [Related]
2. SF2523 inhibits human chondrosarcoma cell growth in vitro and in vivo.
Zhu JX; Xiao JR
Biochem Biophys Res Commun; 2019 Apr; 511(3):559-565. PubMed ID: 30824188
[TBL] [Abstract][Full Text] [Related]
3. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
4. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
Joshi S; Singh AR; Liu KX; Pham TV; Zulcic M; Skola D; Chun HB; Glass CK; Morales GA; Garlich JR; Durden DL
Mol Cancer Ther; 2019 Jun; 18(6):1036-1044. PubMed ID: 31018997
[TBL] [Abstract][Full Text] [Related]
5. Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo.
Qin AC; Li Y; Zhou LN; Xing CG; Lu XS
Cell Physiol Biochem; 2019; 52(4):758-768. PubMed ID: 30933440
[TBL] [Abstract][Full Text] [Related]
6. An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.
De P; Dey N; Terakedis B; Bergsagel PL; Li ZH; Mahadevan D; Garlich JR; Trudel S; Makale MT; Durden DL
Cancer Chemother Pharmacol; 2013 Apr; 71(4):867-81. PubMed ID: 23355037
[TBL] [Abstract][Full Text] [Related]
7. The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.
Peirce SK; Findley HW; Prince C; Dasgupta A; Cooper T; Durden DL
Cancer Chemother Pharmacol; 2011 Aug; 68(2):325-35. PubMed ID: 20972874
[TBL] [Abstract][Full Text] [Related]
8. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
Garlich JR; De P; Dey N; Su JD; Peng X; Miller A; Murali R; Lu Y; Mills GB; Kundra V; Shu HK; Peng Q; Durden DL
Cancer Res; 2008 Jan; 68(1):206-15. PubMed ID: 18172313
[TBL] [Abstract][Full Text] [Related]
9. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.
Mahadevan D; Chiorean EG; Harris WB; Von Hoff DD; Stejskal-Barnett A; Qi W; Anthony SP; Younger AE; Rensvold DM; Cordova F; Shelton CF; Becker MD; Garlich JR; Durden DL; Ramanathan RK
Eur J Cancer; 2012 Dec; 48(18):3319-27. PubMed ID: 22921184
[TBL] [Abstract][Full Text] [Related]
10. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
11. Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.
Loganathan SN; Tang N; Holler AE; Wang N; Wang J
Mol Cancer Ther; 2019 May; 18(5):929-936. PubMed ID: 30926641
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo.
Shen G; Jiang M; Pu J
Biochem Biophys Res Commun; 2018 Jan; 495(1):567-573. PubMed ID: 29133261
[TBL] [Abstract][Full Text] [Related]
13. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.
Andrews FH; Singh AR; Joshi S; Smith CA; Morales GA; Garlich JR; Durden DL; Kutateladze TG
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):E1072-E1080. PubMed ID: 28137841
[No Abstract] [Full Text] [Related]
14. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
Joshi S; Singh AR; Durden DL
Cancer Chemother Pharmacol; 2015 Mar; 75(3):595-608. PubMed ID: 25578041
[TBL] [Abstract][Full Text] [Related]
15. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
Deng M; Wang J; Chen Y; Zhang L; Liu D
Anticancer Drugs; 2015 Apr; 26(4):422-7. PubMed ID: 25588160
[TBL] [Abstract][Full Text] [Related]
16. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
17. Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
Liu Y; Cui B; Qiao Y; Zhang Y; Tian Y; Jiang J; Ma D; Kong B
Int J Gynecol Cancer; 2011 Jan; 21(1):100-5. PubMed ID: 21330835
[TBL] [Abstract][Full Text] [Related]
18. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of BRD4 and PI3K-AKT by SF2523 suppresses human renal cell carcinoma cell growth.
Zhu H; Mao JH; Wang Y; Gu DH; Pan XD; Shan Y; Zheng B
Oncotarget; 2017 Nov; 8(58):98471-98481. PubMed ID: 29228703
[TBL] [Abstract][Full Text] [Related]
20. Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication.
Campbell GR; Bruckman RS; Herns SD; Joshi S; Durden DL; Spector SA
J Biol Chem; 2018 Apr; 293(16):5808-5820. PubMed ID: 29475942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
